Saad A Khan

This Phase 2 trial tests the immunotherapy drug pembrolizumab (Keytruda) in 12 people with advanced anaplastic thyroid cancer, a rare and fast-growing cancer with no standard cure. Participants receive the drug every three weeks to see if tumors shrink or stop growing. The study …